Pfizer
One of the world's largest pharmaceutical companies — vaccines, oncology, and the drug pipeline behind them.
Coverage of Pfizer is holding steady : 2 signals on the latest tracked day, level with its three-week baseline of 2, across 2 domains. That makes it the #151 most-covered of the 157 concerns we track.
Pfizer is steady by its own history. Its normal rhythm is about 2 signals a day across 2 domains. A real move would be a day at 3+ signals — 25% above that baseline, the bar our trend read calls accelerating — or a spread into domains beyond its usual 2. That is the move that would push it up the Wire. It sits on our Health & Bio Desk.
What’s changed
- A 5-month sprint: Behind Pfizer’s $10B deal and Innovent’s global pharma ambition · Fierce Biotech · 2026-06-18
- Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial · Fierce Biotech · 2026-06-22
- Chai brews up $400M series C to fuel AI molecule models used by Lilly, Novartis and Pfizer · Fierce Biotech · 2026-07-14
The crowd’s read, and ours
Coverage momentum and market odds are separate readings — one can move without the other. Prices show what the crowd believes, not our read; our calibrated take is one tap away.